<DOC>
	<DOCNO>NCT00523939</DOCNO>
	<brief_summary>The purpose study determine response rate lymphomatous meningitis leukemic meningitis DepoCyt . The safety DepoCyt , number people respond well study drug , response symptom study drug also determine .</brief_summary>
	<brief_title>DepoCyt Active Lymphomatous Leukemic Meningitis</brief_title>
	<detailed_description>DepoCyt sustained-release formulation chemotherapy drug , cytarabine ( Ara-C ) , use treatment patient lymphomatous leukemic meningitis , complication lymphoma/leukemia characterize spread cancer central nervous system . DepoCyt introduce spinal fluid , needle insert spinal canal reservoir place scalp neurosurgeon . DepoCyt give every two week i.e . week 1 week 3 initially . After second dose , lumbar puncture do check spinal fluid cancer cell . If good response , DepoCyt give every 14 day 6 dos i.e. , week 5 , 7 , 9 , 11 , 13 , 15 every 28 day six dos i.e. , week 19 , 23 , 27 , 31 , 35 , 39 . Blood test lumbar puncture do throughout study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Cytologically confirm , radiographic evidence lymphomatous leukemic meningitis . If CSF cytology negative , patient must MRI/CT brain clinical finding consistent neoplastic meningitis . Karnofsky Performance Score 60 . Age ≥ 18 year . Patients must adequate hematologic , renal liver function . Laboratory Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 white blood cell count &gt; 3,000/mm3 Platelet count ≥ 100 , 000/mm3 BUN serum creatinine must ≤ 1.5 time upper limit laboratory normal Total direct serum bilirubin must ≤ 1.5 time upper limit laboratory normal SGOT SGPT ≤ 3.0 time upper limit laboratory normal Alkaline phosphatase derive liver ≤ 2.0 time upper limit laboratory normal No uncontrolled infection human immunodeficiency virus treat antiretroviral therapy Patients prior CNS radiation , prior intrathecal methotrexate , prior CNS prophylaxis intrathecal intravenous cytarabine methotrexate eligible Written inform consent Experimental/Investigational chemotherapy , immunotherapy , biologic therapy within four week prior study Concurrent systemic chemotherapy high dose methotrexate , high dose cytarabine , high dose thiotepa ( cross blood brain barrier high level ) Patients receive whole brain radiotherapy craniospinal irradiation Previous ( less 2 year diagnosis ) concurrent malignancy sit exception fully treat carcinoma situ cervix , basal cell carcinoma skin , squamous cell carcinoma skin , prostate cancer require ongoing chemotherapy Pregnant lactate woman Known active meningeal infection Evidence obstructive hydrocephalus require neurosurgical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemic Meningitis</keyword>
	<keyword>Lymphomatous Meningitis</keyword>
</DOC>